Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06939127

Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB NSCLC

This is a Phase II single-arm study designed to evaluate the efficacy and safety of cryoablation combined with tislelizumab and platinum-based doublet chemotherapy as neoadjuvant therapy, followed by adjuvant tislelizumab therapy in patients with resectable stage II-IIIB non-small cell lung cancer (NSCLC).

The study consists of a screening phase, a treatment phase (including the neoadjuvant stage, surgery, and adjuvant stage), a safety follow-up period, and a survival follow-up period.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

NSCLC (Non-small Cell Lung Cancer) Bronchial Neoplasms Carcinoma, Bronchogenic Carcinoma, Non-Small-Cell Lung Lung Diseases Lung Neoplasms Neoplasms Neoplasms by Site Respiratory Tract Diseases Respiratory Tract Neoplasms Thoracic Neoplasms

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Tianjin Medical University Cancer Institute and Hospital

Tianjin, 300000, China

Location status: Recruiting

Location contact

Dongsheng Yue Chief Physician of Surgery

CONTACT

[email protected]

+8602223109106

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged ≥18 years at informed consent signing.
  • ECOG performance status of 0 or 1.
  • Histologically confirmed stage II-IIIB NSCLC (AJCC 9th edition).
  • Tumor size ≤5 cm.
  • Deemed suitable for R0 resection by a thoracic surgeon for radical treatment.
  • Adequate cardiopulmonary function for radical surgical resection.
  • Eligible for cryoablation and platinum-based doublet chemotherapy.
  • Adequate blood and organ function, as per laboratory tests within 14 days before enrollment.

Exclusion criteria

  • Prior treatment for current lung cancer, including chemotherapy or radiotherapy.
  • LCNEC diagnosis.
  • Known EGFR mutations or ALK translocations. For non-squamous NSCLC, EGFR mutation status must be confirmed locally or centrally if unknown.

For squamous NSCLC, EGFR testing is not required if status is unknown. ALK translocation testing is not required if status is unknown.

  • Locally advanced, unresectable disease, regardless of stage or metastasis (stage IV). Patients with mediastinal lymph node involvement on CT must undergo sampling for clinical staging to exclude stage IIIB/C.
  • History of interstitial lung disease, non-infectious pneumonitis, or uncontrolled pulmonary fibrosis.
  • Severe chronic or active infections requiring systemic antimicrobials, including tuberculosis.
  • Hospitalization for severe infections within 4 weeks before enrollment. Systemic antibiotic treatment within 2 weeks before enrollment.
  • Active autoimmune disease or history of recurrent autoimmune disease.
  • Exceptions: Well-controlled type 1 diabetes, hypothyroidism on hormone replacement, celiac disease, skin conditions not requiring systemic therapy, or diseases unlikely to recur without provocation.
  • Severe infections requiring systemic treatment within the past 4 weeks.
  • Corticosteroid or immunosuppressive use within 14 days before enrollment, except for specific local, topical, or short-term uses.

Treatment and study plan

Neoadjuvant Cryoablation Combined with Tislelizumab and Chemotherapy

Drug

Eligible patients will start the study treatment (7-14 days between pathological diagnosis and cryoablation). Patients first undergo cryoablation of the primary tumor. Then, 7±3 days after cryoablation, they start treatment with tislelizumab (200 mg) plus platinum-based doublet chemotherapy, given every 3 weeks for 3-4 cycles.

The following platinum-based doublet chemotherapy regimens are allowed in this trial:

  • Cisplatin/carboplatin + pemetrexed (non-squamous NSCLC)
  • Cisplatin/carboplatin + albumin-bound paclitaxel/paclitaxel (squamous NSCLC)

Surgery

Procedure

After completing neoadjuvant therapy, surgery should be performed as soon as possible within 4-6 weeks after the last dose of neoadjuvant therapy.

Adjuvant tislelizumab

Drug

Patients receiving adjuvant therapy must meet the following criteria:

  • ECOG performance status score of 0 or 1
  • Recovery from surgery and adequate organ function as determined by the investigator based on laboratory values During the adjuvant phase, patients will receive tislelizumab as adjuvant therapy. The first dose of tislelizumab (cycle 1 of the adjuvant phase) should be administered within 2-8 weeks after surgery. Patients will continue to receive tislelizumab (400 mg, Q6W) as adjuvant therapy every 6 weeks until one of the following events occurs: completion of 8 cycles of tislelizumab adjuvant therapy, disease recurrence, unacceptable adverse events (AEs), death, or decision by the patient and/or investigator to discontinue study treatment.

Primary outcomes

  1. Pathological Complete Response (pCR) Rate

    Time frame: Up to approximately 8 weeks following completion of neoadjuvant treatment

    pCR rate is defined as the percentage of participants having an absence of residual invasive cancer in resected lung specimens and lymph nodes following completion of neoadjuvant therapy.

Secondary outcomes

  1. Overall Response Rate (ORR)

    Time frame: Up to Study Week 15 (before surgery)

    ORR was defined as the percentage of participants in the analysis population who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) per RECIST 1.1 before surgery.

  2. Radiological downstaging rate

    Time frame: Up to Study Week 15 (before surgery)

    The proportion of patients with radiological T, N, and overall stage reduction (AJCC v9) compared to baseline after neoadjuvant therapy.

  3. Major Pathological Response (mPR) Rate

    Time frame: Up to approximately 8 weeks following completion of neoadjuvant treatment

    mPR rate is defined as the percentage of participants having ≤10% viable tumor cells in the resected primary tumor and all resected lymph nodes following completion of neoadjuvant therapy.

  4. Event Free Survival (EFS)

    Time frame: Up to approximately 2 years

    EFS is defined as the time from randomization until radiographic disease progression, local progression precluding surgery, inability to resect the tumor, local or distant recurrence, or death due to any cause. EFS determined either by biopsy assessed by local pathologist or by investigator-assessed imaging using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1).

  5. Overall Survival (OS)

    Time frame: Up to approximately 2 years

    OS is defined as the time from randomization until death from any cause.

  6. Number of participants experiencing treatment-emergent adverse events (TEAEs)

    Time frame: Up to approximately 2 years

    An AE was defined as any untoward medical occurrence in a study participant administered study drug and which does not necessarily have to have a causal relationship with this study drug. The number of participants who experienced an AE is presented.

  7. Change From Baseline in Neoadjuvant and Adjuvant Phase in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)

    Time frame: Baseline, during the neoadjuvant phase (Cycle 3), during the adjuvant phase (Cycles 1, 3, 5, and 7), and during safety follow-up visits (up to 2 years)

    Change from baseline in QoL score using the EORTC QLQ-C30 will be determined. The EORTC QLQ-C30 is the most widely used cancer-specific, health-related QoL instrument comprised of 30 individual items arranged as both multi-item scales and individual items. Specifically, these items are divided into 5 functional scales (15 items total), 3 symptom scales (7 items total), 6 individual items.

Study contacts

Contact information is provided by the study sponsor or research team.

Donsheng Yue Chief Physician of Surgery

CONTACT

[email protected]

+8602223109106

Sponsors and collaborators

Lead sponsor

Tianjin Medical University Cancer Institute and Hospital

Other

Registry information

Official study title

A Prospective Phase II Study to Explore the Efficacy and Safety of Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant Treatment, Followed by Adjuvant Tislelizumab Therapy in Resectable Stage II-IIIB Non-small Cell Lung Cancer

Important dates

Study start
2025
Primary completion
2026
Study completion
2027
First posted
Apr 22, 2025
Registry last updated
Apr 22, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.